Valuation: Theracryf Plc

Market Cap 6.11M 5.35M 4.94M 4.62M 8.66M 576M 8.84M 59.32M 22.95M 285M 22.93M 22.43M 987M P/E 2026 *
-1.43x
P/E 2027 * -1.74x
Enterprise Value 3.96M 3.47M 3.2M 2.99M 5.61M 373M 5.73M 38.42M 14.87M 184M 14.85M 14.53M 639M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 day-8.51%
1 week-8.51%
Current month-10.42%
1 month-6.52%
3 months+10.26%
6 months+7.50%
Current year+7.50%
1 week 0.21
Extreme 0.2131
0.24
1 month 0.21
Extreme 0.2131
0.26
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.4
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap.
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/05/25Others

Director

422,727,272 19.8499%
04/03/25Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
-8.51%-8.51%-15.69%-93.48% 6.11M
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average -0.75%+3.45%+36.58%+105.69% 22.63B
Weighted average by Cap. +0.26%+5.13%+48.50%+122.67%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.94M -2.71M -2.54M -4.75M -316M -4.85M -32.55M -12.6M -156M -12.58M -12.31M -542M -3.43M -3.01M -2.77M -2.59M -4.87M -324M -4.97M -33.31M -12.89M -160M -12.88M -12.6M -554M
Net Debt -2.15M -1.89M -1.74M -1.63M -3.05M -203M -3.12M -20.89M -8.09M -100M -8.08M -7.9M -348M 453K 398K 366K 343K 643K 42.78M 657K 4.4M 1.7M 21.14M 1.7M 1.67M 73.31M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
26/06/26 GBX 0.2150 -8.51% 8,009,447
25/06/26 GBX 0.2350 0.00% 798,460
24/06/26 GBX 0.2350 0.00% 3,271,066
23/06/26 GBX 0.2350 0.00% 3,809,088
22/06/26 GBX 0.2350 0.00% 3,391,828
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002841USD
Average target price
0.0431USD
Spread / Average Target
+1,418.23%

Annual profits - Rate of surprise